Galleri Test Alternatives: A Guide to Cancer Blood Tests

A single blood test to detect over 50 types of cancer, years before symptoms appear. That is the promise of the Galleri test.

The name appears regularly in the media, yet in Germany the test has hardly become established as a standard part of routine care and, for many, raises more questions than it answers.

What valid Galleri test alternatives are there in Germany?

How do they compare, what do they cost, and for whom are they truly useful?

This article provides an evidence-based assessment.

We analyze the technology, compare the available options, and outline a strategy that goes beyond a single blood test: prevention based on a complete picture of health, not a single laboratory value.

What is the Galleri test – and why is it being discussed?

The Galleri test is a so-called liquid biopsy (Liquid Biopsy). It analyzes cell-free DNA (cfDNA), meaning small DNA fragments that are released into the bloodstream by cells throughout the body. When tumor cells die, they also release their DNA, which can then be detected in the blood as circulating tumor DNA (ctDNA).

The actual innovation lies in the analysis of specific biochemical markers on this DNA: the so-called methylation patterns.

The technology: methylation patterns in liquid biopsy

Cancer cells often show abnormal methylation patterns, comparable to characteristic typos on the DNA that do not occur in healthy tissue. Galleri uses machine learning to identify these cancer-specific patterns in the blood and can make a prediction about the organ in which the tumor may have originated (Cancer Signal Origin). The underlying method was developed by the company GRAIL.

Performance: specificity vs. sensitivity explained

Two metrics are central when evaluating such tests:

Specificity describes how well the test correctly identifies healthy individuals as healthy. High specificity keeps the number of false positives low. Galleri achieves over 99.5% here (GRAIL, 2021): out of 1,000 healthy people, fewer than five receive a falsely positive result.

Sensitivity describes how reliably the test actually detects an existing cancer. Galleri’s overall sensitivity across all cancer types and stages is about 51.5% (Klein et al., 2021), meaning it detects around half of all cancers in the studied population.

Broken down by tumor stage, the picture becomes clearer:

• Stage I (early stage): 16.8 %
• Stage II: 40.4 %
• Stage III: 77.0 %
• Stage IV (advanced): 90.1 %

The more advanced the tumor, the more reliable the detection. In the early stage, where detection would have the greatest clinical benefit, the hit rate remains limited.

NHS Galleri study: What did the largest study show?

The largest randomized study on the Galleri test to date was conducted by the British National Health Service (NHS). More than 140,000 participants were examined. The results show a differentiated picture.

The primary endpoint of the study, a statistically significant reduction in late-stage cancers (III and IV), was not achieved. Positive signals were still observed: the cancer detection rate increased, and in some analyses there was a trend toward a reduction in Stage IV diagnoses.

The medical community therefore draws cautious conclusions. The test is a promising step, but not yet the standalone breakthrough it is often presented as in public.

Availability of Galleri in Germany – the regulatory reality

Despite its visibility, the Galleri test is currently not an established, routinely used screening procedure in the German healthcare system.

Why is Galleri not yet widely established in Germany?

For broad use in the European healthcare system, a medical device would need to be evaluated from both a regulatory and clinical perspective in such a way that it could be recommended for population-based screening. For the Galleri test, such broad integration into routine care has not yet been established. The regulatory process is also still ongoing in the United States; GRAIL reported in January 2026 that it had completed its submission for FDA review.

The test is therefore neither included in the benefits catalogue of statutory health insurance (GKV) nor part of standardized screening programs.

Galleri off-label or private: costs and alternatives

Some private physicians and specialized clinics in Germany offer the Galleri test as an individual health service (IGeL) or as part of private preventive care programs. The cost is borne entirely by the patient and ranges between 800 and 1,200 euros, similar to the US price of around 950 US dollars.

For privately insured individuals (PKV), reimbursement is not guaranteed. Whether the tariff covers the test depends on the individual case, and purely preventive measures without a specific suspicion of disease are rarely reimbursed.

Alternatives to the Galleri test in Germany – a systematic comparison

The limited availability of Galleri has created room for other technologies and tests in Germany. Here are the most important ones at a glance.

PanTum Detect: the German EDIM approach

PanTum Detect is currently one of the best-known alternatives in Germany, above all through partnerships with insurers such as HanseMerkur. Unlike Galleri, it is based on EDIM technology (Epitop Detection in Monocytes) and does not analyze tumor DNA.

Instead, it measures two biomarkers (TKTL1 and Apo10) on the surface of macrophages. The theory: these immune cells detect tumor cells and take up parts of them, which changes the concentration of these biomarkers on their surface.

Critical classification

The method is viewed critically by oncology experts. The German Cancer Society currently does not recommend EDIM-based tests for cancer early detection or diagnostics. A large part of the available data comes from studies involving patients who were already ill; the test’s value in screening asymptomatic populations has not been sufficiently established.

Shield test: FDA-approved colorectal cancer focus

The Shield test from Guardant Health also analyzes cfDNA, focuses exclusively on colorectal cancer, and received FDA approval in July 2024. It is currently not available on the German market but shows the direction in which specialized blood tests are developing.

CancerSEEK: the Johns Hopkins multi-analyte model

CancerSEEK was developed by researchers at Johns Hopkins University and combines genetic mutation analyses in 16 genes with eight protein biomarkers in the blood. This combined approach is intended to improve accuracy compared to DNA-only tests. CancerSEEK is not yet commercially available in Germany.

YEARS (TruCheck): integrated liquid biopsy in Berlin

The Berlin-based preventive clinic YEARS uses the TruCheck blood test in the Evolve® and Ultimate® programs. This test analyzes circulating tumor cells (CTCs) and is designed to provide indications of a wide range of solid tumor types.

The difference compared to isolated testing

The key difference lies in the setting: at YEARS, the liquid biopsy is not used as a standalone screening tool but as part of a comprehensive diagnostic program. The results are interpreted by physicians in the context of additional examinations such as imaging and laboratory analyses in order to better assess suspicious signals.

Performance, cost, availability

Performance metrics come from different study populations and are not directly comparable. They are intended as a general orientation.

Blood test screening vs. standard screening: when does it make sense?

No blood test replaces established screening procedures: colonoscopy for colorectal cancer, mammography for breast cancer, Pap smear for cervical cancer. MCED tests are designed as a supplement, not a replacement.

Who should consider a multi-cancer test?

MCED tests are currently most useful for:

People aged 50 and above, as cancer risk increases significantly with age.

People with increased risk due to strong family history or known genetic risk factors.

People who want more comprehensive screening beyond standard recommendations and who understand and can handle the consequences of a positive result.

The issue of false positives: psychological and economic costs

Even with a specificity of 99.5%, 5 out of 1,000 healthy individuals receive a false alarm. This almost always leads to anxiety, stress, and a cascade of further investigations: PET-CT, MRI, biopsies. This costs time, money, and places a significant burden on those affected. Medical counseling before the test and follow-up care afterward are therefore not optional add-ons but medically necessary.

What is the best diagnostic strategy? – a layered model

A single blood test provides one layer of data. A robust prevention strategy requires several.

1. The foundation: a comprehensive medical baseline

Before highly specialized tests such as a liquid biopsy can be used effectively, a solid baseline of health status is required. The YEARS Core® program provides this in a single day:

87+ biomarkers, far beyond standard panels, including ApoB and hs-CRP for cardiovascular health as well as the HOMA index as a marker of insulin resistance. Many of these values remain unmeasured for years in routine care, even though they can provide early indications of cardiovascular disease or metabolic syndrome.

Functional imaging using extended ultrasound of the heart, abdominal organs, thyroid, and blood vessels, combined with performance diagnostics measuring VO₂max and lung function via body plethysmography. Cardiorespiratory fitness, or VO₂max, is among the strongest predictors of long-term mortality.

AI-supported skin screening to detect skin changes as well as retinal analysis using AI-based fundus imaging complete the program.

2. The extension: integrated multi-omics diagnostics

Based on this foundation, targeted advanced diagnostics can be applied. The YEARS Evolve® program combines TruCheck with whole-body MRI: the blood test searches for molecular signals, while MRI simultaneously provides a structural map of the entire body.

The YEARS Ultimate® program adds further layers: whole-exome and whole-genome sequencing analyze numerous cancer-relevant genes for hereditary risk factors. A microbiome analysis captures the composition of the gut flora, whose role is increasingly being studied, even if direct clinical implications in individual screening remain limited.

Frequently asked questions (FAQ)

Does my private insurance (PKV) cover the blood test for cancer detection?

Most PKV tariffs do not reimburse an isolated blood test as an IGeL service. YEARS programs are billed according to the German fee schedule for physicians (GOÄ). Because medically relevant findings often arise during diagnostics, such as vitamin deficiencies, elevated inflammatory markers, or insulin resistance, the likelihood of partial reimbursement by private insurance increases. Further information can be found in our frequently asked questions about YEARS.

How long does it take to receive results?

Liquid biopsy results are typically available within one to two weeks. At YEARS, you receive a 60+ page health report approximately two weeks after the diagnostic day, along with a detailed strategy consultation with a physician. All results—blood test, MRI, biomarkers—are discussed together and translated into concrete recommendations.

What does a “positive result” mean?

A positive result does not confirm cancer. It is a signal that triggers further diagnostic steps. An integrated program like YEARS offers a structural advantage: additional diagnostic information is already available and can help contextualize the signal before further invasive procedures are initiated.

Conclusion: your personal screening roadmap

Blood tests for early cancer detection such as Galleri or PanTum Detect are tools with potential. The evidence base is promising but not yet complete. None of these tests should replace established standard screening.

For a robust, actionable prevention strategy, a stepwise approach is recommended:

Build a foundation: start with a comprehensive, physician-guided baseline assessment that goes beyond a simple blood panel. The YEARS Core® program provides this multi-dimensional baseline in a single day.

Integrate instead of isolate: for deeper early detection, choose an approach that combines liquid biopsy with whole-body MRI. The YEARS Evolve® program integrates both methods into a structured workflow.

Ensure medical guidance: data without interpretation is of limited value. Results must be assessed by experienced physicians and translated into a prioritized action plan.

A single blood test gives you one data point. An integrated diagnostic program gives you a strategy. If you are ready to take the next step, schedule a consultation.

Sources

GRAIL, LLC. (2021). The PATHFINDER Study: A Prospective Study of a Test for Multi-Cancer Early Detection. ClinicalTrials.gov Identifier: NCT04241796.

GRAIL, LLC. (2024). NHS-Galleri trial primary endpoint analysis and top-line results presented at 2024 ASCO Annual Meeting. Press release.

GRAIL, LLC. (2026). GRAIL submits FDA Premarket Approval application for the Galleri multi-cancer early detection test. Press release.

HanseMerkur Versicherungsgruppe. (2024). Krebs-Scan: Die innovative Krebsvorsorge. Product page.

Klein, E. A., et al. (2021). Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Annals of Oncology, 32(9), 1167–1177. DOI: 10.1016/j.annonc.2021.05.806.

U.S. Food and Drug Administration (FDA). (2024). SHIELD Blood Test Approval.